Literature DB >> 28697341

MUC-king with HIF May Rewire Pyrimidine Biosynthesis and Curb Gemcitabine Resistance in Pancreatic Cancer.

Chi V Dang1.   

Abstract

In this issue of Cancer Cell, Singh and colleagues report a role for MUC1-induced HIF expression in rewiring ribose synthesis, which drives pyridimine production as a possible resistance mechanism to gemcitabine, adding to complexity and multiple paths to resistance.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28697341     DOI： 10.1016/j.ccell.2017.06.006

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  4 in total

1.  RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine.

Authors:  Wenchao Liu; Yujia Mao; Xiaoyi Zhang; Yaonan Wang; Jianhui Wu; Shurui Zhao; Shiqi Peng; Ming Zhao
Journal:  Int J Nanomedicine       Date:  2019-09-06

2.  The synergic inhibitory effects of dark tea (Camellia sinensis) extract and p38 inhibition on the growth of pancreatic cancer cells.

Authors:  Ke Zheng; Qin Zhao; Qing Chen; Weiqun Xiao; Yuedeng Jiang; Yuhui Jiang
Journal:  J Cancer       Date:  2019-10-21       Impact factor: 4.207

3.  Exploring the action of RGDV-gemcitabine on tumor metastasis, tumor growth and possible action pathway.

Authors:  Xiaoyi Zhang; Jinhuan Zhang; Wenchao Liu; Yaonan Wang; Jianhui Wu; Shurui Zhao; Ming Zhao; Shiqi Peng
Journal:  Sci Rep       Date:  2020-09-25       Impact factor: 4.379

Review 4.  Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions.

Authors:  Molly C Holbrook; Dakota W Goad; Valery Z Grdzelishvili
Journal:  Cancers (Basel)       Date:  2021-03-09       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.